Regulatory authorities in six countries have granted 10 sales authorizations for Yondelis. Five of those authorizations are for Yondelis (trabectedin) in combination with Caelyx (pegylated liposomal doxorubicin) for treating relapsed platinum-sensitive ovarian cancer, in Bangladesh, Costa Rica, Kuwait, Moldavia and Saudi Arabia The other five authorizations are for Yondelis for soft tissue sarcoma, in Bangladesh,...
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
